Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct:262:108708.
doi: 10.1016/j.pharmthera.2024.108708. Epub 2024 Aug 21.

C-type natriuretic peptide (CNP): The cardiovascular system and beyond

Yasmin A Dickinson  1 , Amie J Moyes  1 , Adrian J Hobbs  2
Affiliations
Free article
Review

C-type natriuretic peptide (CNP): The cardiovascular system and beyond

Yasmin A Dickinson et al. Pharmacol Ther. 2024 Oct.
Free article

Abstract

C-type natriuretic peptide (CNP) represents the 'local' member of the natriuretic peptide family, functioning in an autocrine or paracrine capacity to modulate a hugely diverse portfolio of physiological processes. Whilst the best-characterised of these regulatory roles are in the cardiovascular system, akin to its predominantly endocrine siblings atrial (ANP) and brain (BNP) natriuretic peptides, CNP governs many additional, unrelated mechanisms including bone growth, gamete maturation, auditory processing, and neuronal integrity. Furthermore, there is currently great interest in mimicking the biological activity of CNP for therapeutic gain in many of these disparate organ systems. Herein, we provide an overview of the physiology, pathophysiology and pharmacology of CNP in both cardiovascular and non-cardiovascular settings.

Keywords: C-type natriuretic peptide; Central nervous system; Cyclic GMP; G-protein coupled receptor; Heart; Kidney; Metabolism; Natriuretic peptide receptor; Vasculature.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest A.H. is a scientific advisory board member/consultant for Palatin Technologies Inc., Pharmain Corp. and Novo Nordisk. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Adrian Hobbs reports financial support was provided by British Heart Foundation. Yasmin Dickinson reports financial support was provided by Biotechnology and Biological Sciences Research Council. Adrian Hobbs reports a relationship with Novo Nordisk that includes: consulting or advisory and travel reimbursement. Adrian Hobbs reports a relationship with PharmaIN Corp that includes: consulting or advisory. Adrian Hobbs reports a relationship with Palatin Technologies Inc. that includes: consulting or advisory and funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

MeSH terms

Substances

LinkOut - more resources